Form 4: Director Receives Stock Grant and Options

Richard Ronald, a Director at Emergent BioSolutions Inc., was granted restricted stock units and stock options on April 30, 2026, as part of his compensation for board service.

Summary

• Richard Ronald, a Director of Emergent BioSolutions Inc. (EBS), received a grant of 25,344 restricted stock units (RSUs) and 11,296 stock options on April 30, 2026.
• The RSUs are part of an annual grant under the Company's Stock Incentive plan for board and committee service. Each RSU represents a right to one share of common stock upon vesting.
• The stock options were also granted under the Company's Stock Incentive Plan for board and committee service, with an exercise price of $7.99 per share.
• Both the RSUs and stock options are subject to vesting conditions, requiring the reporting person to remain a member of the Company's board of directors through the annual grant vesting date, which is the day prior to the one-year anniversary of the grant date.
• Following these transactions, Richard Ronald beneficially owns 123,761 shares of common stock directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it represents routine compensation for a director and does not contain new financial performance data or strategic shifts.

Positives

• Director compensation through equity awards aligns the interests of management with shareholders.
• The grant of RSUs and stock options indicates continued commitment to retaining experienced board members.
• The exercise price of the stock options ($7.99) is below the current market price, suggesting potential value for the director upon vesting.

Negatives

• The filing does not contain any negative financial or operational information.

Risks

• Vesting is contingent on continued board membership, meaning the director could forfeit these awards if they step down before the vesting date.
• The value of the RSUs and options is subject to the future performance and stock price of Emergent BioSolutions Inc.

Future Outlook

The future outlook for the granted RSUs and stock options is dependent on the reporting person's continued service on the board and the future performance of Emergent BioSolutions Inc.'s stock price. The options have an expiration date of April 30, 2033.

Management Comments

• The RSUs represent a right to receive one share of Emergent BioSolutions Inc. common stock upon vesting.
• Each stock option represents a right to purchase one share of the Company's common stock upon vesting at the exercise price.

Industry Context

StockSavvy.ai notes that equity grants to directors are a standard practice in the biotechnology and pharmaceutical industry to incentivize long-term commitment and align executive interests with shareholder value. The structure of these grants, including vesting periods and exercise prices, is typical for board compensation.

Stakeholder Impact

• Shareholders: The equity grants align director interests with shareholders, potentially leading to decisions that enhance long-term shareholder value. The grants themselves do not immediately dilute ownership but represent future potential share issuance.
• Employees: This filing does not directly impact employees.
• Creditors: This filing has no direct impact on creditors.
• Suppliers: This filing has no direct impact on suppliers.
• Customers: This filing has no direct impact on customers.

Next Steps

• The RSUs and stock options will vest on the day prior to the one-year anniversary of the grant date, provided the reporting person remains a director.
• The stock options can be exercised at any time after vesting until their expiration date of April 30, 2033.

Key Dates

Keywords

Form 4, SEC Filing, Emergent BioSolutions, EBS, Director Compensation, Restricted Stock Units, Stock Options, Equity Grant, Beneficial Ownership, Insider Trading